Drug Approval | April 14, 2025
Aurobindo receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg
The product will be launched in Q1FY26
The product will be launched in Q1FY26
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
Findings likely to generate hypotheses about potential new uses of drugs
The portfolio includes branded injectable cephalosporines for infectious diseases
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
The freshly infused capital will primarily be deployed towards expansion and research & development
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
Subscribe To Our Newsletter & Stay Updated
